Company Description
Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease.
The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion.
It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection.
The company was founded in 2019 and is based in New York, New York.
| Country | United States |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | James M. Rolke |
Contact Details
Address: 5 West 21st Street New York, New York United States | |
| Website | https://www.revbiosciences.com |
Stock Details
| Ticker Symbol | REVBW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001810560 |
| CUSIP Number | 76135L119 |
| ISIN Number | US76135L1199 |
| Employer ID | 84-3898466 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James M. Rolke | Chief Executive Officer & Director |
| Chester Stanley Zygmont III | Chief Financial Officer & Corporate Secretary |
| Carol Odle | Senior Director of Clinical Projects |
| Sandra Vedrick | Vice President of Human Resources & Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | DEFA14A | Filing |
| Jan 07, 2025 | 8-K | Current Report |
| Jan 02, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Dec 20, 2024 | 424B3 | Filing |
| Dec 19, 2024 | S-3/A | [Amend] Filing |
| Dec 16, 2024 | DEF 14A | Filing |
| Dec 12, 2024 | 8-K | Current Report |
| Dec 12, 2024 | S-3 | Filing |
| Dec 06, 2024 | 8-K | Current Report |
| Dec 05, 2024 | PRE 14A | Filing |